Biohaven (NYSE:BHVN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Biohaven logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan raised Biohaven’s price target to $35 from $14 and maintained an “overweight” rating, implying 154.77% upside from the prior close.
  • Analyst views are mixed: Biohaven has a consensus “Moderate Buy” rating and an average price target of $22.57, with ratings ranging from strong buy to sell.
  • Biohaven is a clinical-stage biotech developing treatments for serious diseases; its investigational candidates are not approved and it has no marketed products.
  • Five stocks to consider instead of Biohaven.

Biohaven (NYSE:BHVN - Get Free Report) had its target price lifted by equities research analysts at JPMorgan Chase & Co. from $14.00 to $35.00 in a report released on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target would indicate a potential upside of 154.77% from the stock's previous close.

A number of other brokerages have also recently weighed in on BHVN. Citigroup reissued a "buy" rating on shares of Biohaven in a research note on Friday, September 18th. Wall Street Zen cut shares of Biohaven from a "hold" rating to a "sell" rating in a report on Saturday, November 7th. Robert W. Baird set a $48.00 price target on shares of Biohaven in a report on Thursday, October 22nd. Royal Bank Of Canada upped their price target on shares of Biohaven from $19.00 to $22.00 and gave the company a "sector perform" rating in a research report on Friday, October 23rd. Finally, Raymond James Financial reaffirmed a "strong-buy" rating on shares of Biohaven in a research note on Thursday, October 8th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $22.57.

Check Out Our Latest Stock Analysis on Biohaven

Biohaven Price Performance

Biohaven stock traded up $0.84 during mid-day trading on Thursday, hitting $13.74. The company's stock had a trading volume of 2,197,080 shares, compared to its average volume of 2,751,926. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 21.23. The stock has a market capitalization of $2.08 billion, a P/E ratio of -3.57 and a beta of 1.36. Biohaven has a twelve month low of $8.03 and a twelve month high of $18.24. The stock's fifty day moving average price is $13.41 and its two-hundred day moving average price is $12.37.

Hedge Funds Weigh In On Biohaven

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Coastal Bridge Advisors LLC lifted its position in Biohaven by 43.2% in the third quarter. Coastal Bridge Advisors LLC now owns 32,979 shares of the company's stock worth $440,000 after purchasing an additional 9,957 shares during the period. Integrated Wealth Concepts LLC lifted its stake in shares of Biohaven by 8.4% during the third quarter. Integrated Wealth Concepts LLC now owns 13,716 shares of the company's stock valued at $183,000 after acquiring an additional 1,063 shares during the period. Algert Global LLC grew its position in shares of Biohaven by 318.1% during the 3rd quarter. Algert Global LLC now owns 1,291,773 shares of the company's stock worth $17,245,000 after buying an additional 982,793 shares during the period. Allworth Financial LP grew its holdings in Biohaven by 10.4% during the 3rd quarter. Allworth Financial LP now owns 8,672 shares of the company's stock worth $116,000 after acquiring an additional 814 shares during the period. Finally, Quarry LP bought a new position in Biohaven during the third quarter worth about $200,000. Institutional investors own 88.78% of the company's stock.

Biohaven Company Profile

(Get Free Report)

Biohaven Ltd. is a clinical-stage biopharmaceutical company developing treatments for neurological, immunological and other serious diseases. Its research programs include potential therapies for epilepsy and autoimmune conditions, as well as medicines designed to target disease-related proteins and antibodies. The company's pipeline includes investigational candidates that act on ion channels and immune pathways. These programs are in development and are not approved medicines; Biohaven does not have a marketed product portfolio.

Recommended Stories

Analyst Recommendations for Biohaven (NYSE:BHVN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Biohaven Right Now?

Before you consider Biohaven, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.

While Biohaven currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines